John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.
John McCamant has spent 35 years on the front lines of biotech investing as an equities analyst and in venture capital. He has also edited the Medical Technology Stock Letter since the year 2000. In this session, he'll tell you about the methodology he uses to sift through hundreds of biotech companies to find the best in class drugs like MDGL for long-term growth. Plus, John will highlight the most attractive biotech opportunities in this premier growth sector for the rest of 2023 and beyond.
John McCamant, editor of the Medical Technology Stock Letter, says he expects a bidding war for MYOV and important catalysts from MDGL, TCRT, and PGEN in Q4.
The Biotech indices have bounced 30% in 30 days (June 16-July 16) as over-sold conditions and biotech/drugs being immune to economic/recession fears have attracted new fund flows.
Medical Technology Stock Letter
The Medical Technology Stock Letter (“MTSL“) is published 24 times per year and offers unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility.Learn More